Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APOBEC3A | P31941 | 2/20 | 0.38 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.34 |
| ▸ | KDR | P35968 | 2/20 | 0.34 |
| ▸ | FLT1 | P17948 | 1/20 | 0.34 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.33 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21879818 | 0.80 | APOBEC3A (0.42) | APOBEC3AAPOBEC3GKDM4EHPGDALDH1A1 | |
| SCHEMBL71364 | 0.79 | APOBEC3A (0.46) | APOBEC3AAPOBEC3GKDM4EALDH1A1FGFR1 | |
| SCHEMBL31333068 | 0.78 | APOBEC3A (0.38) | APOBEC3AAPOBEC3GKDM4EALDH1A1FGFR1 | |
| SCHEMBL23992032 | 0.78 | APOBEC3A (0.38) | APOBEC3AAPOBEC3GKDM4ETSHRFGFR1 | |
| SCHEMBL23930860 | 0.78 | APOBEC3A (0.38) | APOBEC3AAPOBEC3GKDM4EALDH1A1FGFR1 | |
| SCHEMBL21879844 | 0.77 | HCAR3 (0.35) | NOTUMKDM4EHPGDALDH1A1TSHR | |
| SCHEMBL21721120 | 0.77 | ALDH1A1 (0.39) | NOTUMKDM4EHPGDALDH1A1TSHR | |
| SCHEMBL31336867 | 0.74 | KDM4E (0.44) | APOBEC3AAPOBEC3GNOTUMKDM4EHPGD | |
| SCHEMBL31336866 | 0.74 | KDM4E (0.44) | APOBEC3AAPOBEC3GNOTUMKDM4EHPGD | |
| SCHEMBL31332992 | 0.74 | NPC1 (0.43) | APOBEC3AAPOBEC3GNOTUMKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4139299-B1 | KRAS G12D PROTEIN INHIBITORS | TAIHO PHARMACEUTICAL CO LTD (JP) | 2025-12-17 | — | — | EP | disclosed |
| US-12065430-B2 | Indazole compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-08-20 | — | — | US | disclosed |
| EP-3871673-B1 | NOVEL INDAZOLE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2024-01-03 | — | — | EP | disclosed |
| US-20230181536-A1 | ANTICANCER COMBINATION THERAPY WITH N-(1-ACRYLOYL-AZETIDIN-3-YL)-2-((1H-INDAZOL-3-YL)AMINO)METHYL)-1H-IMIDAZOLE-5-CARBOXAMIDE INHIBITOR OF KRAS-G12C | TAIHO PHARMACEUTICAL CO LTD (JP) | 2023-06-15 | — | — | US | disclosed |
| US-20230174518-A1 | KRAS G12D PROTEIN INHIBITORS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-06-08 | — | — | US | disclosed |
| US-20230174518-A1 | KRAS G12D PROTEIN INHIBITORS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-06-08 | — | — | US | disclosed |
| US-20230174518-A1 | KRAS G12D PROTEIN INHIBITORS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-06-08 | — | — | US | disclosed |
| EP-4139299-A1 | KRAS G12D PROTEIN INHIBITORS | Taiho Pharmaceutical Co., Ltd. (JP) | 2023-03-01 | — | — | EP | disclosed |
| US-20210395234-A1 | NOVEL INDAZOLE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO. LTD. (JP) | 2021-12-23 | — | — | US | disclosed |
| WO-2021215545-A1 | ANTICANCER COMBINATION THERAPY WITH N-(1-ACRYLOYL-AZETIDIN-3-YL)-2-((1H-INDAZOL-3-YL)AMINO)METHYL)-1H-IMIDAZOLE-5-CARBOXAMIDE INHIBITOR OF KRAS-G12C | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-10-28 | — | — | WO | disclosed |
| WO-2021215544-A1 | KRAS G12D PROTEIN INHIBITORS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-10-28 | — | — | WO | disclosed |
| WO-2020085493-A1 | NOVEL INDAZOLE COMPOUND OR SALT THEREOF | 大鵬薬品工業株式会社 | 2020-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174518-A1 | KRAS G12D PROTEIN INHIBITORS | KRAS, NRAS, HRAS | APOBEC3A 3064/4885APOBEC3G 3136/4885NOTUM 4094/4885 |
| US-12065430-B2 | Indazole compound or salt thereof | RCOR3, H1-3, BICRA | APOBEC3A 3280/4885APOBEC3G 3381/4885NOTUM 2919/4885 |
| US-20230181536-A1 | ANTICANCER COMBINATION THERAPY WITH N-(1-ACRYLOYL-AZETIDIN-3-YL)-2-((1H-INDAZOL-3-YL)AMINO)METHYL)-1H-IMIDAZOLE-5-CARBOXAMIDE INHIBITOR OF KRAS-G12C | KRAS, NRAS, HRAS | APOBEC3A 3625/4885APOBEC3G 3800/4885NOTUM 4712/4885 |
| US-20210395234-A1 | NOVEL INDAZOLE COMPOUND OR SALT THEREOF | HDAC11, RCOR3, BICRA | APOBEC3A 3856/4885APOBEC3G 3954/4885NOTUM 3375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.